This joint study by Imavita and the biopharmaceutical group Ipsen, published in late 2023 in Toxicon, compares the effects of a single injection of aboBoNT-A (botulinum toxin) with
How IMAVITA applies the 3Rs in preclinical studies thanks to its models and the use of imaging Applying the 3Rs in preclinical studies: IMAVITA’s vision and practices Before
👩‍🔬👨‍🔬 Meet the faces behind the science! At Imavita, our greatest strength is our team. Behind every study, every image, and every result, there’s a group of passionate
Unlocking Reliable Preclinical Studies with Imavita’s Quality Management System (QMS) At Imavita, our commitment to quality is at the heart of everything we do. As a preclinical CRO,
All the team from Imavita joins me to wish you a happy and successful new year 2025!A lot of exciting news to come on 2025! Follow us on
All the team at Imavita joins me to wish you season’s greetings.We’ve had a great year at Imavita with bigger facilities, exciting developments and new collaborators.Wishing you a
We’ve Moved! We are excited to announce that Imavita has a new home!As part of our ongoing growth and commitment to serving our clients, we have relocated to
IMAVITA and all its team wish to all customers, suppliers, collaborators and families, a Happy New Year and Best Wishes for 2024!
We are pleased to announce that Imavita team recently co-authored a publication withIpsen about AbobotulinumtoxinA improvement on skin properties and sebum quality in Rhino mouse acne model. The
©2013-2025 Imavita S.A.S. All rights reserved. | Legal mentions.